Study of emapalumab for low blood counts after CAR T-cell therapy
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a drug called emapalumab to help people whose blood counts stay low for weeks after CAR T-cell therapy for certain types of lymphoma. The goal is to see if the drug can help the body recover normal blood cell production.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had a type of CAR T-cell therapy (like axi-cel, tisa-cel, or liso-cel) for your lymphoma.
- Between 30 and 90 days after that therapy, you have low blood counts that are moderate to severe (low white blood cells, low platelets, or low hemoglobin).
- You are at least 18 years old.
- You are able to get out of bed and take care of yourself most of the day (ECOG performance status 0, 1, or 2).
- Your kidneys, liver, and oxygen levels are working well enough based on standard blood tests and a breathing test.
- You agree to use birth control (if applicable) and to have bone marrow biopsies before and after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called emapalumab can reduce serious side effects from CAR-T cell therapy, a treatment for large B-cell lymphoma that has come back or not responded to earlier treatments. If you qualify, you would receive emapalumab alongside your CAR-T treatment to help make it safer.
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
This study tests whether umbilical cord blood cells can help people whose blood counts stay dangerously low after immune-based cancer treatments like CAR-T or bispecific antibodies. The treatment aims to boost your blood cell recovery and reduce the need for transfusions.
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
Hear when a new Cytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.